Callan Family Office’s Insmed INSM Stock Holding History

Callan Family Office’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$485K	Buy	2,968 +197	+7%	+$30.3K	0.01%	778
2025 Q4	$482K	Buy	+2,771	New	+$506K	0.01%	795

Other funds holding INSM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Callan Family Office's INSM Position: Q1 2026 in Review

Callan Family Office increased its Insmed (INSM) stake by 7.1% in Q1 2026, buying an estimated $30.3K and bringing the position to 2,968 shares worth $485K. The position accounts for 0.01% of the portfolio, ranked #778.

Callan Family Office first reported a position in INSM in Q4 2025 and has held it in 2 quarters since. 669 funds tracked by Wall St. Rank hold INSM as of Q1 2026.

Callan Family Office held 2,968 shares of Insmed worth $485K as of Q1 2026.
Callan Family Office bought 197 Insmed shares in Q1 2026, an estimated $30.3K.
Insmed made up 0.01% of Callan Family Office's portfolio in Q1 2026, its #778 holding.
Callan Family Office first reported a position in Insmed in Q4 2025 and has held it in 2 quarters since.
669 funds tracked by Wall St. Rank held Insmed as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.